<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363274">
  <stage>Registered</stage>
  <submitdate>15/11/2012</submitdate>
  <approvaldate>19/11/2012</approvaldate>
  <actrnumber>ACTRN12612001217897</actrnumber>
  <trial_identification>
    <studytitle>Erectile dysfunction in male patients with fatty liver disease</studytitle>
    <scientifictitle>Erectile dysfunction in male patients with Non Alcoholic Steatohepatitis</scientifictitle>
    <utrn>NIL</utrn>
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non Alcoholic Steatohepatitis</healthcondition>
    <healthcondition>Erectile dysfunction</healthcondition>
    <healthcondition>Metabolic Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>We aim to observe the infertility or erectile dysfunction status in NASH patients. Since most NASH patients have accompanying metabolic syndrome we also aim to see how many NASH patients having metabolic syndrome have also high erectile dysfunction. Participants are assessed on one occasion only over a period of about 1 hour via the International Index of Erectile Function 5 point questionnaire.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary outcome 1: Total score of "International Index of Erectile Function"</outcome>
      <timepoint>Time Point: Baseline (at the enrollement phase)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary outcome 2: Level of liver damage assessed by the liver biopsy.</outcome>
      <timepoint>Time Point: Baseline (at the enrollement phase)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary outcome: Demographic findings and the presence of accompanying metabolic syndrome in each patient. Metabolic syndrome will be assessed by the insulin resistance blood sugar and lipid profiles in serum and routine measurements of blood tension, body weight, height, hip and waist circumference.</outcome>
      <timepoint>Time Point: Baseline (at the enrollement phase)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male patients with  Nonalcoholic steatohepatitis.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Female patients
Patients who have overt diabetes that use oral antidiabetic agents or insulin
Patients using antihyperlipidemic agents, antihypertensives, testesteron derivatives
Chronic liver disease due to the causes other than Nonalcoholic steatohepatitis, such as chronic hepatitis B, C, alcohol, hemachromatosis, Wilson's disease
Diagnosed malignant disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>26/11/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Marmara University Faculty of Medicine</primarysponsorname>
    <primarysponsoraddress>T.C. Saglik Bakanligi, Marmara Universitesi Pendik E.A.H.
Mimar Sinan Caddesi No: 41 

34780 Ust Kaynarca, Pendik, Istanbul</primarysponsoraddress>
    <primarysponsorcountry>Turkey</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Turkey</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Previously, the incidence of erectile dysfunction has been shown to be increased in patients having metabolic syndrome (MS). Nonalcoholic steatohepatitis (NASH) is a clinical entity which was advocated as the liver manifestation of MS. We aim to screen the male NASH patients with regard to erectile dysfunction using the 5 point International Index of Erectile Function (IIEF-5) questionnaire. 
Our secondary end point is to evaluate the demographic findings of NASH patients and test the association of erectile dysfunction with the components of MS.
Our secondary end point is to evaluate the demographic findings of NASH patients and test the assciation of erectile dysfunction with the components of MS.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Marmara University, Medical School Ethics Committee</ethicname>
      <ethicaddress>Tibbiye Cad. No:38
 34668 Haydarpasa - Istanbul</ethicaddress>
      <ethicapprovaldate>15/09/2011</ethicapprovaldate>
      <hrec>B.30.2.MAR.0.01.02/AEK/114</hrec>
      <ethicsubmitdate />
      <ethiccountry>Turkey</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Deniz Guney Duman</name>
      <address>T.C. S. B. Marmara Universitesi Pendik E.A.H. Gastroenteroloji Bolumu, Fevzi Cakmak Mah. Mimar Sinan Cad. No:41 Ust Kaynarca 34780 Pendik/ISTANBUL</address>
      <phone>+90 216 6254684</phone>
      <fax />
      <email>gduman@marmara.edu.tr</email>
      <country>Turkey</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Deniz Guney Duman</name>
      <address>T.C. S. B. Marmara Universitesi Pendik E.A.H. Gastroenteroloji Bolumu, Fevzi Cakmak Mah. Mimar Sinan Cad. No:41 Ust Kaynarca 34780 Pendik/ISTANBUL</address>
      <phone>+90 216 6254684</phone>
      <fax />
      <email>gduman@marmara.edu.tr</email>
      <country>Turkey</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Deniz Guney Duman</name>
      <address>T.C. S. B. Marmara Universitesi Pendik E.A.H. Gastroenteroloji Bolumu, Fevzi Cakmak Mah. Mimar Sinan Cad. No:41 Ust Kaynarca 34780 Pendik/ISTANBUL</address>
      <phone>+90 216 6254684</phone>
      <fax />
      <email>gduman@marmara.edu.tr</email>
      <country>Turkey</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>